Page 137 - 《中国药房》2021年第1期

[31] ZHAO C，HAN SY，LI PP，et al. Pharmacokinetics of gefi- centrations of dasatinib have a clinical impact on the fre-
tinib：roles of drug metabolizing enzymes and transpor- quency of dasatinib dose reduction and interruption in
ters[J]. Curr Drug Deliv，2017，14（2）：282-288. chronic myeloid leukemia：an analysis of the DARIA 01
[32] KOBAYASHI H，SATO K，NIIOKA T，et al. Effects of study[J]. Int J Clin Oncol，2018，23（5）：980-988.
polymorphisms in CYP2D6 and ABC transporters and [45] MIURA M. Therapeutic drug monitoring of imatinib，nilo-
side effects induced by gefitinib on the pharmacokinetics tinib，and dasatinib for patients with chronic myeloid leu-
of the gefitinib metabolite，O-desmethyl gefitinib[J]. Med kemia[J]. Biol Pharm Bull，2015，38（5）：645-654.
Oncol，2016. DOI：10.1007/s12032-016-0773-5. [46] HOŘÍNKOVÁ J，ŠÍMA M，SLANAŘ O. Pharmacokine-
[33] ZHAO YY，LI S，ZHANG Y，et al. The relationship be- tics of dasatinib[J]. Prague Medical Report，2019，120（2）：
tween drug exposure and clinical outcomes of non-small 52-63.
cell lung cancer patients treated with gefitinib[J]. Med On- [47] 张昕怡，侯珂，贾月萍，等.治疗药物监测指导下达沙替尼
col，2011，28（3）：697-702. 个体化给药的病例分析[J].中国临床药理学杂志，2020，
[34] XIN S，ZHAO YY，WANG XD，et al. The Dissociation of 36（3）：341-343.
geftinib trough concentration and clinical outcome in [48] JOHNSON FM，AGRAWAL S，BURRIS H，et al. Phase 1
NSCLC patients with EGFR sensitive mutations[J]. Sci pharmacokinetic and drug-interaction study of dasatinib in
Rep，2015. DOI：10.1038/srep12675. patients with advanced solid tumors[J]. Cancer，2010，116
[35] YASUMURO O，UCHIDA S，KASHIWAGURA Y，et al. （6）：1582-1591.
Changes in gefitinib，erlotinib and osimertinib pharmaco- [49] LEVÊQUE D，BECKER G，BILGER K，et al. Clinical
kinetics under various gastric pH levels following oral ad- pharmacokinetics and pharmacodynamics of dasatinib[J].
ministration of omeprazole and vonoprazan in rats[J]. Xe- Clin Pharmacokinet，2020，59（7）：849-856.
nobiotica，2018，48（11）：1106-1112. [50] TAKAHASHI N，MIURA M，NIIOKA T，et al. Influence
[36] MAI HX，HUANG J，ZHANG YY，et al. In-vivo relation of H2-receptor antagonists and proton pump inhibitors on
between plasma concentration of sorafenib and its safety dasatinib pharmacokinetics in Japanese leukemia pa-
in Chinese patients with metastatic renal cell carcinoma：a tients[J]. Cancer Chemother Pharmacol，2012，69（4）：
single-center clinical study[J]. Oncotarget，2017，8（26）： 999-1004.
43458-43469. [51] MIURA M，TAKAHASHI N. Routine therapeutic drug
[37] 史蕤，李然，赵冰清，等.索拉非尼血药浓度与疗效和不良 monitoring of tyrosine kinase inhibitors by HPLC-UV or
反应的关系以及在肝细胞癌治疗应用[J].中国临床药理 LC-MS/MS methods[J]. Drug Metab Pharmacokinet，
学杂志，2015，31（17）：1793-1795. 2016，31（1）：12-20.
[38] THOMAS S，THANKAPPAN AP，PADMA UD. Thera- [52] MOTZER RJ，HOOSEN S，BELLO CL，et al. Sunitinib
peutic drug monitoring of sorafenib in hepatocellular car- malate for the treatment of solid tumours：a review of cur-
cinoma patients[J]. Ther Drug Monit，2020，42（2）：345- rent clinical data[J]. Expert Opin Investig Drugs，2006，15
347. （5）：553-561.
[39] KAWAHARA D，OZAWA S，KIMURA T，et al. Clinical [53] MENDEL DB，LAIRD AD，XIN X，et al. In vivo antitu-
pharmacokinetics and pharmacodynamics of transarterial mor activity of SU11248，a novel tyrosine kinase inhibitor
chemoembolization and targeted therapies in hepatocellu- targeting vascular endothelial growth factor and plate-
lar carcinoma[J]. Phys Med，2016，32（4）：557-561. let-derived growth factor receptors：determination of a
[40] BA HL，MBATCHI L，GATTACCECA F，et al. Pharmaco- pharmacokinetic/pharmacodynamic relationship[J]. Clin
genetics and pharmacokinetics modeling of unexpected Cancer Res，2003，9（1）：327-337.
and extremely severe toxicities after sorafenib intake[J]. [54] WESTERDIJK K，KRENS SD，VAN DER GRAAF WT，
Pharmacogenomics，2020，21（3）：173-179. et al. The relationship between sunitinib exposure and
[41] KARBOWNIK A，SOBAŃSKA K，GRABOWSKI T，et both efficacy and toxicity in real-world patients with renal
al. In vivo assessment of the drug interaction between cell carcinoma and gastrointestinal stromal tumour[J]. Br
sorafenib and paracetamol in rats[J]. Cancer Chemother J Clin Pharmacol，2020. DOI：10.1111/bcp.14332.
Pharmacol，2020，85（6）：1039-1048. [55] HOUK BE，BELLO CL，POLAND B，et al. Relationship
[42] 徐怀友，束超，邵凤，等. LC-MS/MS 法测定人血浆中达 between exposure to sunitinib and efficacy and tolerability
沙替尼的浓度及两种片剂的生物等效性研究[J].中国药 endpoints in patients with cancer：results of a pharmacoki-
房，2016，27（8）：1051-1054. netic/pharmacodynamic Meta-analysis[J]. Cancer Che-
[43] CHRISTOPHER LJ，CUI DH，WU CY，et al. Metabolism mother Pharmacol，2010，66（2）：357-371.
and disposition of dasatinib after oral administration to hu- [56] RAHAVENDRAN SV，PITHAVALA YK，BELLO C，
mans[J]. Drug Metab Dispos，2008，36（7）：1357-1364. et al. Comparison of clinical drug-drug interaction study
[44] MIZUTA S，SAWA M，TSURUMI H，et al. Plasma con- results for sunitinib and axitinib with an in silico tool[J].

中国药房 2021年第32卷第1期 China Pharmacy 2021 Vol. 32 No. 1 ·127 ·